| Frank, Ian |
NCT06033209: A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV |
|
|
| Recruiting | 1 | 84 | US | N332-GT5 gp140 (IM, Bolus), N332-GT5 gp140 (IM, Fractioned), N332-GT5 gp140 (SC, Bolus), N332-GT5 gp140 (SC, Fractioned), SMNP (IM, Bolus), SMNP (IM, Fractioned), SMNP (SC, Bolus), SMNP (SC, Fractioned) | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services | HIV | 02/25 | 02/25 | | |
NCT05854381: To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV |
|
|
| Active, not recruiting | 1 | 95 | US, RoW | VIR-1388, Placebo | Vir Biotechnology, Inc., National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network | HIV I Infection | 11/25 | 11/27 | | |
NCT04801758: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study |
|
|
| Completed | N/A | 18 | RoW | Analytical Treatment Interruption | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | HIV Infection | 07/24 | 07/24 | | |
| Mannheimer, Sharon |
| Active, not recruiting | 3 | 719 | Japan, US, RoW | Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label) | National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies | MPOX | 10/24 | 09/25 | | |
| Completed | N/A | 100 | US | SMARTest mobile app for COVID-19 self-testing | Columbia University | COVID-19 | 09/23 | 09/23 | | |
| Goepfert, Paul |
NCT04101838: B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults |
|
|
| Recruiting | 4 | 50 | US | Fluzone, influenza vaccine, Flucelvax, Fluzone High-Dose, high dose influenza vaccine, Fluad, adjuvanted influenza vaccine | University of Alabama at Birmingham | Influenza | 05/25 | 05/25 | | |
| Recruiting | 3 | 2000 | US | BCG (Tokyo 172) vaccine, Placebo, sodium glutamate | Henry M. Jackson Foundation for the Advancement of Military Medicine, United States Department of Defense, Uniformed Services University of the Health Sciences | Tuberculosis Infection | 09/27 | 09/27 | | |
NCT05854381: To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV |
|
|
| Active, not recruiting | 1 | 95 | US, RoW | VIR-1388, Placebo | Vir Biotechnology, Inc., National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network | HIV I Infection | 11/25 | 11/27 | | |
| Baden, Lindsey Robert |
PLAT, NCT04224311: Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors |
|
|
| Active, not recruiting | 4 | 102 | US | Menactra | Brigham and Women's Hospital | Preventive Immunization; Meningitis | 10/23 | 04/24 | | |
| Recruiting | 4 | 148 | US | Sofosbuvir/velpatasvir, Epclusa, Monitoring, Sofosbuvir/velpatasvir (Epclusa) | Brigham and Women's Hospital | Hepatitis C, Awaiting Organ Transplant | 12/23 | 12/23 | | |
| Not yet recruiting | 3 | 260 | NA | Cessation of antibiotics, Stop antibiotics | Brigham and Women's Hospital, Dana-Farber Cancer Institute | Hematologic Malignancy, Febrile Neutropenia, Antibiotic Stewardship | 03/26 | 03/28 | | |
| Active, not recruiting | 2 | 964 | US | Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control | Kanecia Obie Zimmerman | Long COVID, Long Covid19 | 08/24 | 03/25 | | |
NCT06059391: CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant |
|
|
| Recruiting | 2 | 216 | US | Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Granulocyte Colony-Stimulating Factor, Colony Stimulating Factor 3, Colony-Stimulating Factor (Granulocyte), Colony-Stimulating Factor 3, CSF3, G CSF, G-CSF, GCSF, Granulocyte Colony Stimulating Factor, Pluripoietin, Hematopoietic Cell Transplantation Conditioning Regimen, HCT Conditioning Regimen, HSCT Conditioning Regimen, Stem Cell Transplant Conditioning, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, CMV-MVA Triplex Vaccine, Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Pheresis, Apheresed, Apheresis, Blood Component Removal, Collection, Apheresis/Leukapheresis, Hemapheresis, Placebo Administration, Stem Cell Mobilization Therapy, Chemomobilization, Hematopoietic Stem Cell Mobilization, Mobilization Therapy, Stem-cell mobilization | City of Hope Medical Center, National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma | 01/27 | 01/28 | | |
NCT04355585: Revisiting the Mechanism of the Anti-inflammatory Effect of Colchicine |
|
|
| Recruiting | 1 | 18 | US | Colchicine Tablets, Placebo oral tablet | Brigham and Women's Hospital, Harvard Medical School (HMS and HSDM) | Colchicine Mechanism of Action | 04/23 | 04/23 | | |
NCT04794218: A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath |
|
|
| Active, not recruiting | 1 | 114 | US, RoW | rVSV∆G-LASV-GPC, Placebo/Diluent | International AIDS Vaccine Initiative, George Washington University, Brigham and Women's Hospital, Redemption Hospital, East-West Medical Research Institute | Lassa Fever, Lassa Virus Infection | 12/23 | 03/24 | | |
NCT05657782: First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers |
|
|
| Recruiting | 1 | 53 | US | PanChol | Brigham and Women's Hospital | Cholera, Cholera Vaccine Toxicity | 12/24 | 12/25 | | |
NCT04915768: Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants. |
|
|
| Active, not recruiting | 1 | 52 | US | CH505 TF chTrimer, 3M-05-AF, Aluminum hydroxide suspension | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 08/25 | 08/25 | | |
NCT06033209: A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV |
|
|
| Recruiting | 1 | 84 | US | N332-GT5 gp140 (IM, Bolus), N332-GT5 gp140 (IM, Fractioned), N332-GT5 gp140 (SC, Bolus), N332-GT5 gp140 (SC, Fractioned), SMNP (IM, Bolus), SMNP (IM, Fractioned), SMNP (SC, Bolus), SMNP (SC, Fractioned) | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services | HIV | 02/25 | 02/25 | | |
| Recruiting | N/A | 660 | US | Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care | Duke University, National Heart, Lung, and Blood Institute (NHLBI) | Long COVID, Long Covid19, Long Covid-19 | 10/25 | 01/26 | | |
NCT04801758: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study |
|
|
| Completed | N/A | 18 | RoW | Analytical Treatment Interruption | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | HIV Infection | 07/24 | 07/24 | | |
| Sobieszczyk, Magdalena |
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection |
|
|
| Completed | 2 | 45 | US, RoW | Glecaprevir/Pibrentasvir (G/P), Mavyret | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C Infection, HIV Infection | 05/23 | 08/23 | | |
RSV OA=ADJ-023, NCT05921903: A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above |
|
|
| Active, not recruiting | 2 | 387 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA Investigational Vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 07/24 | 06/25 | | |
EMBRACE, NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) |
|
|
| Active, not recruiting | 2 | 128 | US | VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20 | ViiV Healthcare | HIV Infections | 11/24 | 05/26 | | |
NCT06033209: A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV |
|
|
| Recruiting | 1 | 84 | US | N332-GT5 gp140 (IM, Bolus), N332-GT5 gp140 (IM, Fractioned), N332-GT5 gp140 (SC, Bolus), N332-GT5 gp140 (SC, Fractioned), SMNP (IM, Bolus), SMNP (IM, Fractioned), SMNP (SC, Bolus), SMNP (SC, Fractioned) | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services | HIV | 02/25 | 02/25 | | |
| Recruiting | N/A | 175 | US | Individualized Feedback | Columbia University, Merck Sharp & Dohme LLC | HIV Prevention, Pre-exposure Prophylaxis | 10/26 | 10/26 | | |
NCT04367857: ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers |
|
|
| Recruiting | N/A | 1000 | US | COVID-19 Serology, Health Care Worker Survey | Columbia University | Covid-19, Coronavirus Infection, Coronavirus | 03/25 | 03/26 | | |
| Sumner, Shonda E |
NCT06267872: A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum |
|
|
| Not yet recruiting | 1 | 42 | US, RoW | CD4BS CH505M5 Pr-NP1, CH505TF chTrimer, 3M-052-AF (labeled as AP 60-702), Aluminum Hydroxide Suspension (Alum), Alhydrogel, ACU-026-001-1 (labeled as empty LNP) | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, Duke University, Access to Advanced Health Institute (AAHI) | HIV | 12/25 | 09/26 | | |
NCT04915768: Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants. |
|
|
| Active, not recruiting | 1 | 52 | US | CH505 TF chTrimer, 3M-05-AF, Aluminum hydroxide suspension | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 08/25 | 08/25 | | |
NCT05828095: A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV |
|
|
| Active, not recruiting | 1 | 20 | US | INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg) | National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1-infection | 03/25 | 03/25 | | |
NCT05903339: Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV |
|
|
| Active, not recruiting | 1 | 36 | US | V3G CH848 Pr-NP1 60mcg, 3M-052-AF 5mcg, Alum 500 mcg, V3G CH848 mRNA-Tr2 50mcg, ACU-026-001-1 2.0mg, V3G CH848 Pr-NP1 100mcg | National Institute of Allergy and Infectious Diseases (NIAID) | Hiv | 08/25 | 08/25 | | |
| Erdmann, Nathan |
| Active, not recruiting | 2 | 964 | US | Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control | Kanecia Obie Zimmerman | Long COVID, Long Covid19 | 08/24 | 03/25 | | |
| Recruiting | N/A | 660 | US | Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care | Duke University, National Heart, Lung, and Blood Institute (NHLBI) | Long COVID, Long Covid19, Long Covid-19 | 10/25 | 01/26 | | |
| Leader, CRS |
HVTN 135, NCT04607408: Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants |
|
|
| Completed | 1 | 38 | RoW | CH505TF gp120, GLA-SE adjuvant, Placebo | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 07/24 | 07/24 | | |
NCT04860323: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study |
|
|
| Active, not recruiting | N/A | 13 | RoW | Analytical Treatment Interruption | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | HIV Infection | 02/25 | 02/25 | | |
